Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

TD Cowen analyst Ritu Baral maintained a Hold rating on Sarepta Therapeutics today and set a price target of $24.00. The company’s shares closed last Friday at $20.08. According to TipRanks.com, Baral ...

Stay up-to-date on Wall Street's latest analyst calls, stock downgrades, and upgrades for major companies like Sarepta, Cisco, and more.

Sarepta Therapeutics slashed its share price by 44 percent last week following price target cuts from two investment companies.

Understanding Analyst Ratings: A Comprehensive Breakdown An in-depth analysis of recent analyst actions unveils how financial experts perceive Sarepta Therapeutics.

In a market note, Oppenheimer significantly lowered its price target for Sarepta Therapeutics, Inc. (NASDAQ:SRPT) to $45 from $123 previously, marking a 63-percent downside.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is one of the Massive Sell-Offs: These 10 Stocks Shockingly Nosedived. Sarepta Therapeutics slashed its share price by 44 percent last week following price ...

Shares of Sarepta traded over 7% lower on Wednesday afternoon. Sarepta announced the death of a second patient following treatment with Elevidys earlier this month.

The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, Trimble is now the #23 analyst pick, moving up by 1 spot. This rank is ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on June 30, 2025 that were previously approved by the Compensation ...

Review quarterly and annual revenue, net income, and cash flow for Sarepta Therapeutics Inc (SRPT:XMEX) stock through the last fiscal year.